• COX enzyme
• Drug discovery
• Inflammation
• Molecular dynamic simulation

• Imidazoles/chemistry
• Imidazoles/pharmacology
• Imidazoles/chemical synthesis
• Cyclooxygenase 2 Inhibitors/chemistry
• Cyclooxygenase 2 Inhibitors/pharmacology
• Cyclooxygenase 2 Inhibitors/chemical synthesis
• Molecular Dynamics Simulation
• Cyclooxygenase 2/metabolism
• Drug Design
• Structure-Activity Relationship
• Humans
• Molecular Docking Simulation
• Molecular Structure

• 3D microvessels-on-chip model
• endothelial dysfunction
• hypoxia
• hypoxia inducible factor – 1 alpha
• nitric oxide metabolites
• signaling lipids

• Corynoxine
• Cyclooxygenase-2
• Lung adenocarcinoma
• Metastasis
• PI3K/AKT pathway
• Proliferation

• Humans
• Animals
• Phosphatidylinositol 3-Kinases/metabolism
• Proto-Oncogene Proteins c-akt/metabolism
• Cell Proliferation/drug effects
• Cyclooxygenase 2/genetics
• Cyclooxygenase 2/metabolism
• Adenocarcinoma of Lung/drug therapy
• Adenocarcinoma of Lung/genetics
• Adenocarcinoma of Lung/pathology
• Mice
• Lung Neoplasms/drug therapy
• Lung Neoplasms/genetics
• Lung Neoplasms/pathology
• Signal Transduction/drug effects
• Cell Movement/drug effects
• Mice, Nude
• Apoptosis/drug effects
• A549 Cells
• Xenograft Model Antitumor Assays
• Epithelial-Mesenchymal Transition/drug effects
• Gene Expression Regulation, Neoplastic/drug effects
• Cell Line, Tumor

• 2024ZL922 Science and Technology Program of Traditional Chinese Medicine in Zhejiang Province
• 2022J032 Natural Science Foundation of Ningbo Municipality
• LQ20H160010 Natural Science Foundation of Zhejiang Province
• 2022-B19 The Project of Ningbo Leading Medical & Health Discipline
• The Project of Ningbo Leading Medical & Health Discipline

• Clinical translation
• Eicosanoids
• Epilipids
• Lipid mediators
• Lipidomics
• Oxylipins

• Oxylipins/blood
• Oxylipins/metabolism
• Humans
• Animals
• Biomedical Research

• Biomarker
• Energy metabolism
• Metabolomics
• Myocardial injury
• Shen Bai formula
• Viral myocarditis sequelae

• Rats
• Animals
• Tandem Mass Spectrometry
• Drugs, Chinese Herbal/pharmacology
• Drugs, Chinese Herbal/therapeutic use
• Metabolomics/methods
• Arachidonic Acid
• Energy Metabolism
• Biomarkers
• Doxorubicin
• Linoleic Acids
• Chromatography, High Pressure Liquid

• Humans
• Mice
• Animals
• Apolipoproteins/metabolism
• Apolipoproteins/pharmacology
• Lipocalins/metabolism
• Lipocalins/pharmacology
• Receptors, Lysosphingolipid/metabolism
• Apolipoproteins M
• Inflammation
• Lipoproteins, HDL/pharmacology
• Lipoproteins, HDL/metabolism
• Lysophospholipids/pharmacology
• Lysophospholipids/metabolism
• Sphingosine

• R33 CA263705 NCI NIH HHS
• R35 HL135775 NHLBI NIH HHS
• R01 EY031715 NEI NIH HHS
• K08 HL161259 NHLBI NIH HHS
• R01 HL167723 NHLBI NIH HHS
• R35 HL135821 NHLBI NIH HHS

• King Saud University

• Parkinson’s disease
• ferroptosis
• ingredient
• machine learning
• natural product
• transcriptomics

• National Natural Science Foundation of China

• AA
• COX-2
• PGs
• protozoa
• protozoan infection

• Animals
• Humans
• Cyclooxygenase 2
• Protozoan Infections
• Animal Husbandry
• Inflammation
• Prostaglandins

• aspirin
• chemoprevention
• cyclooxygenase
• prostacyclin
• prostaglandin
• thromboxane

• bioactive lipid
• linoleic acid
• lipid mediators
• mass spectrometry
• octadecanoid

• Humans
• Oxylipins
• Eicosanoids/metabolism
• Fatty Acids, Unsaturated/metabolism
• Fatty Acids
• Inflammation

• fluorocoxib q
• cox-2
• redox
• activatable
• inflammation imaging

• Animals
• Cyclooxygenase 2/metabolism
• Cyclooxygenase 2 Inhibitors/pharmacology
• Fluorescent Dyes/chemistry
• Neoplasms
• Oxidation-Reduction

• P50 CA128323 NCI NIH HHS
• R01 CA089450 NCI NIH HHS
• R01 CA260958 NCI NIH HHS
• T32 CA217834 NCI NIH HHS

Extensive research has been carried out to understand and elucidate the mechanisms of paraoxonase 1 (PON1) in the development of diseases including cancer, cardiovascular diseases, neurological diseases, and inflammatory diseases. This review focuses on the relationship between PON1 and cancer. The data suggest that PON1, oxidative stress, chronic inflammation, and cancer are closely linked. Certainly, the gene expression of PON1 will remain challenging to study. Therefore, targeting PON1, redox-sensitive pathways, and transcription factors promise prevention and therapy in the development of several diseases, including cancer.

Trees are vital resources for economic, environmental, and industrial growth, supporting human life directly or indirectly through a wide variety of therapeutic compounds, commodities, and ecological services. Pterocarpus marsupium Roxb. (Fabaceae) is one of the most valuable multipurpose forest trees in India and Sri Lanka, as it is cultivated for quality wood as well as pharmaceutically bioactive compounds, especially from the stem bark and heartwood. However, propagation of the tree in natural conditions is difficult due to the low percentage of seed germination coupled with overexploitation of this species for its excellent multipurpose properties. This overexploitation has ultimately led to the inclusion of P. marsupium on the list of endangered plant species. However, recent developments in plant biotechnology may offer a solution to the overuse of such valuable species if such advances are accompanied by technology transfer in the developing world. Specifically, techniques in micropropagation, genetic manipulation, DNA barcoding, drug extraction, delivery, and targeting as well as standardization, are of substantial concern. To date, there are no comprehensive and detailed reviews of P. marsupium in terms of biotechnological research developments, specifically pharmacognosy, pharmacology, tissue culture, authentication of genuine species, and basic gene transfer studies. Thus, the present review attempts to present a comprehensive overview of the biotechnological studies centered on this species and some of the recent novel approaches for its genetic improvement.

Because of gastrointestinal irritation and kidney toxicity associated with non-steroidal anti-inflammatory drugs and the cardiovascular problems of Coxibs use, developing novel anti-inflammatory agents with reduced toxicity and improved selectivity remains a major challenge. Depending on our previous work, a novel series of pyridopyrimidinones IIIa-i has been synthesized via reaction of 6-amino-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one (I) and phenyldiazenyl aromatic aldehydes (IIa-i). All the new constructed compounds were fully characterized by elemental and spectral analysis.

The target compounds IIIa–i were investigated for their potential towards COX inhibition, anti-inflammatory properties using carrageenan induced edema model in rat paw, and the ulcer indices of the most active members.

The ethyl pyridopyrmidinone-benzoates IIIf, IIIg and IIIh showed superior inhibitory activity of carrageenan induced edema to celecoxib. Furthermore, the pyridopyrimidinones IIId, IIIf, IIIg, and IIIi exerted improved COX-2 inhibitory activity (IC₅₀ = 0.67–1.02 µM) comparing to celecoxib (IC₅₀ = 1.11 µM). Moreover, the gastric ulcerogenic potential assay of compounds IIIf–h revealed their lower ulcerogenic liability than indomethacin with comparable effect to celecoxib.

Virtual docking investigation of the most active candidates IIId, IIIf, IIIg and IIIi in the active site of COX-2 enzyme showed that these compounds implied interaction and binding motif similar to the cocrystallized ligand bromocelecoxib.

• 2-Substituted benzoxazole
• COX-2 inhibitor
• anti-inflammatory
• coxibs
• docking
• ethanol

In the last decade, Autism has broadened and often shifted its diagnostics criteria, allowing several neuropsychiatric and neurological disorders of known etiology. This has resulted in a highly heterogeneous spectrum with apparent exponential rates in prevalence. I ask if it is possible to leverage existing genetic information about those disorders making up Autism today and use it to stratify this spectrum. To that end, I combine genes linked to Autism in the SFARI database and genomic information from the DisGeNET portal on 25 diseases, inclusive of non-neurological ones. I use the GTEx data on genes’ expression on 54 human tissues and ask if there are overlapping genes across those associated to these diseases and those from SFARI-Autism. I find a compact set of genes across all brain-disorders which express highly in tissues fundamental for somatic-sensory-motor function, self-regulation, memory, and cognition. Then, I offer a new stratification that provides a distance-based orderly clustering into possible Autism subtypes, amenable to design personalized targeted therapies within the framework of Precision Medicine. I conclude that viewing Autism through this physiological (Precision) lens, rather than viewing it exclusively from a psychological behavioral construct, may make it a more manageable condition and dispel the Autism epidemic myth.

• Autism
• genes
• neurodevelopment
• neurological disorders
• neuropsychiatric disorders
• stratification
• tissues

• Albizia amara
• Anti-inflammatory
• COX-2
• Molecular docking
• Molecular dynamics
• Phyla nodiflora

Notwithstanding extensive research into fertility problems in mares, pregnancy rates have remained low mainly because of endometrial inflammation (endometritis). In the field of equine research, endometrial explants have been used to carry out in vitro studies of the mare’s endometrium. However, there has been no wide-ranging assessment of relative stability of this model over time. The aim of this study was to perform an in-depth transcriptomic assessment of endometrial explants over a culture period of 72 h and assess if they are representative of the whole mare. Explants at 24 h demonstrated significant changes when compared to biopsies at 0 h as expected. Even though gene expression changes were seen between 24 and 48 h of culture, prior to this window changes were dominated by the effects of explanting and culture and subsequently, transcription was generally compromised. Our results, therefore have defined the optimal period when explants can be used to study equine endometritis and how the endometrium is modulated during inflammation. It highlights the use of abattoir derived samples to understand the physiology and pathophysiology of the equine endometrium, negating the need to collect repeated uterine biopsies from living mares.

Persistent mating-induced endometritis is a major cause of poor fertility rates in the mare. Endometritis can be investigated using an ex vivo equine endometrial explant system which measures uterine inflammation using prostaglandin F_2α as a biomarker. However, this model has yet to undergo a wide-ranging assessment through transcriptomics. In this study, we assessed the transcriptomes of cultured endometrial explants and the optimal temporal window for their use. Endometrium harvested immediately post-mortem from native pony mares (n = 8) were sampled (0 h) and tissue explants were cultured for 24, 48 and 72 h. Tissues were stored in RNALater, total RNA was extracted and sequenced. Differentially expressed genes (DEGs) were defined using DESeq2 (R/Bioconductor). Principal component analysis indicated that the greatest changes in expression occurred in the first 24 h of culture when compared to autologous biopsies at 0 h. Fewer DEGs were seen between 24 and 48 h of culture suggesting the system was more stable than during the first 24 h. No genes were differentially expressed between 48 and 72 h but the low number of background gene expression suggested that explant viability was compromised after 48 h. ESR1, MMP9, PTGS2, PMAIP1, TNF, GADD45B and SELE genes were used as biomarkers of endometrial function, cell death and inflammation across tissue culture timepoints. STRING assessments of gene ontology suggested that DEGs between 24 and 48 h were linked to inflammation, immune system, cellular processes, environmental information processing and signal transduction, with an upregulation of most biomarker genes at 24 h. Taken together our observations indicated that 24–48 h is the optimal temporal window when the explant model can be used, as explants restore microcirculation, perform wound healing and tackle inflammation during this period. This key observation will facilitate the appropriate use of this as a model for further research into the equine endometrium and potentially the progression of mating-induced endometritis to persistent inflammation between 24 and 48 h.

• RNA-seq
• endometritis
• endometrium
• equine
• explant
• gene expression
• reproduction
• tissue culture
• transcriptome

• allergy
• antiinflammation
• ethnopharmacology
• phytosteroids

• PGE2
• anti-inflammatory
• pyrimidoazepine
• selective COX-2 inhibition

• Coptidis Rhizoma
• GO and KEGG
• Kawasaki disease
• Western blotting
• network pharmacology

Acute lung injury (ALI) together with acute respiratory distress syndrome (ARDS) are associated with high rate of mortality and morbidity in patients. In the current study, the anti-inflammatory effects of continentalic acid (CNT) in LPS-induced acute lung injury model was explored.

The acute lung injury model was established by administering LPS (5 mg/kg) intraperitonealy. Following LPS administration, the survival rate, temperature changes and lung Wet/Dry ratio were assessed. The antioxidants (GSH, GST, Catalase and SOD) and oxidative stress markers (MDA, NO, MPO) were evaluated in all the treated groups. Similarly, the cytokines such as IL-1β, IL-6 and TNF-α were analyzed using ELISA assay. The histological changes were determined using H and E staining, while Nrf2 and iNOS level were determined using immunohistochemistry analysis. The molecular docking analysis was performed to assess the pharmacokinetics parameters and interaction of the CNT with various protein targets.

The results showed that CNT dose dependently (10, 50 and 100 mg/kg) reduced mortality rate, body temperature and lungs Wet/Dry ratio. CNT post-treatment significantly inhibited LPS-induced production of pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α. The CNT post-treatment markedly improved the hematological parameters, while significantly reduced the MPO (indicator of the neutrophilic infiltration) activity compared to the LPS treated group. Furthermore, the CNT (100 mg/kg) post-administration remarkably inhibited the lung Wet/Dry ratio. The CNT (100 mg/kg) treated group showed marked reduction in the oxidative stress markers such as malonaldehyde (MDA) and Nitric oxide (NO) concentration, while induced the level of the anti-oxidant enzymes such as GST, GSH, Catalase and SOD. Similarly, the CNT markedly reduced the iNOS expression level, while induced the Nrf2 protein expression. Additionally, the molecular docking study showed significant binding interaction with the Nrf2, p65, Keap1, HO-1, IL-1β, IL-6, TNF-α and COX-2, while exhibited excellent physicochemical properties.

The CNT showed marked protection against the LPS-induced lung injury and improved the behavioral, biochemical and histological parameters. Furthermore, the CNT showed significant interaction with several protein targets and exhibited better physicochemical properties.

• Antioxidants
• Continentalic acid
• Cytokines
• Inflammation
• LPS

Objectives of this study were to determine effects of meloxicam administered in 2 forms on IgG uptake, growth, and health of preweaned calves. Sixteen Holstein bulls and 14 heifers with a body weight (BW) of 44.3 ± 5.24 kg were blocked by birth date in a randomized complete block design. Calves were removed from the dam before suckling, weighed, and randomly assigned to 1 of 3 treatments: (1) colostrum replacer (CR) at 0 h with no meloxicam (control; CON), (2) 1 mg/kg of BW of meloxicam in pill form before CR (PL), or (3) 1 mg/kg of BW of meloxicam mixed in solution with CR (SL). Calves were fed 675 g of dry matter of CR, providing a volume of 3 L and 180 g of IgG. Blood samples were collected at 0 h to analyze initial IgG and ketone concentrations, and at 6, 12, 18, and 24 h to analyze IgG uptake. At 24 h, calves were fed 432 g of dry matter of 24% crude protein milk replacer (MR) split in 2 feedings, and free choice starter and water until 42 d. Weekly blood samples were analyzed for glucose, plasma urea nitrogen, and ketone concentrations. Time of consumption of MR, BW, length, hip and withers height, and heart girth were recorded weekly. All calves achieved adequate transfer of immunity. Meloxicam did not affect apparent efficiency of absorption, serum total protein, or IgG uptake at 6, 18, and 24 h; however, meloxicam-treated calves had lesser IgG concentrations at 12 h (24.40 and 22.59 g/L for PL and SL, respectively) compared with CON (28.47 g/L). Meloxicam treatment did not affect BW. Calves that received PL tended to gain length at a faster rate (0.24 cm/d) than those that received SL (0.19 cm/d). Meloxicam treatment did not affect MR intake, time of consumption of MR, total dry matter intake, or feed efficiency. Meloxicam-treated calves tended to consume more starter (560.4 and 515.4 g/d for PL and SL, respectively) than those that received CON (452.6 g/d). Ketone levels tended to be greater in meloxicam-treated calves (0.15 and 0.17 mmol/L for PL and SL, respectively), suggesting improved rumen development compared with those that received CON (0.12 mmol/L). Meloxicam treatment did not affect plasma urea nitrogen . Glucose concentrations of calves that received PL (73.2 mg/dL) were less than those that received SL (83.3 mg/dL). Results of this study suggest that meloxicam given at 0 h offers positive effects on starter intake, and possibly rumen development, of preweaned dairy calves. Treatment PL, as compared with SL, offered positive results for rumen development, indicated by lower blood glucose levels.

• calf
• colostrum
• immunoglobulin G
• meloxicam
• nonsteroidal anti-inflammatory drug

• anti-inflammatory
• antioxidant
• antiproliferative
• bioactivities
• fatty acids
• functional foods
• lipids

• Breast Neoplasms/drug therapy
• Breast Neoplasms/metabolism
• Cell Line, Tumor
• Cytotoxins/chemistry
• Cytotoxins/pharmacology
• Female
• Free Radical Scavengers/chemistry
• Free Radical Scavengers/pharmacology
• Fucus/chemistry
• Gracilaria/chemistry
• Humans
• Lipids/chemistry
• Lipids/pharmacology
• Porphyra/chemistry
• Ulva/chemistry

• CESAM (UIDP/50017/2020+UIDB/50017/2020), QOPNA (FCT UID/QUI/00062/2019) and LAQV/REQUIMTE (UIDB/50006/2020) and Mass Spectrometry Network /RNEM (LISBOA-01-0145-FEDER-402-022125) Fundação para a Ciência e a Tecnologia
• Omics 4 Algae: Lipidomic tools for chemical phenotyping, traceability and valorisation of seaweeds from aquaculture as a sustainable source of high added-value compounds (POCI-01-0145-FEDER-030962) Fundação para a Ciência e a Tecnologia
• SmartBioR - Smart Valorization of Endogenous Marine Biological Resources Under a Changing Climate" (Centro-01-0145-FEDER-000018), Programa Operacional Regional do Centro

• Acetobacter syzygii
• Lactobacillus plantarum
• Lactobacillus salivarius
• Oral cancer
• Probiotics

• Anti-inflammatory agents, non-steroidal
• Cholangiopancreatography, endoscopic retrograde
• Pancreatitis

• Acute Disease
• Administration, Rectal
• Anti-Inflammatory Agents, Non-Steroidal/adverse effects
• Cholangiopancreatography, Endoscopic Retrograde/adverse effects
• Humans
• Pancreatitis/diagnosis
• Pancreatitis/etiology
• Pancreatitis/prevention & control
• Pharmaceutical Preparations

• aldo-keto reductase (AKR)
• biosynthesis of oxidized lipids
• cyclooxygenase (COX)
• cytochrome P450
• lipoxygenase (LOX)
• oxidized phospholipids
• oxylipins
• sterols and steroid hormones

• Aldo-Keto Reductases/metabolism
• Animals
• Cytochrome P-450 Enzyme System/metabolism
• Humans
• Lipids/biosynthesis
• Lipids/chemistry
• Lipoxygenase/metabolism
• Oxidation-Reduction
• Prostaglandin-Endoperoxide Synthases/metabolism

• BB/N015932/1 Biotechnology and Biological Sciences Research Council
• BB/L001942/1 Biotechnology and Biological Sciences Research Council
• 203014/Z/16/Z Wellcome Trust

PNO1 (partner of Nob1) was known as a RNA‐binding protein in humans, and its ortholog PNO1 was reported to participate ribosome and proteasome biogenesis in yeasts. Yet there have been few studies about its functions in mammalian cells, and so far its role in human cells has never been reported, especially in urinary bladder cancer (UBC).We interrogated the cellular functions and clinical significance of PNO1 in, and its molecular mechanism through microarrays and bioinformatics analysis. Our findings support that PNO1 participates in promoting proliferation and colonogenesis, while reducing apoptosis of UBC cells, and is also predicted to be associated with the migration and metastasis of UBC PNO1 knockdown (KD) attenuated the tumorigenesis ability of UBC in mouse. PNO1 KD led to the altered expression of 1543 genes that are involved in a number of signalling pathways, biological functions and regulation networks. CD44, PTGS2, cyclin D1, CDK1, IL‐8, FRA1, as well as mTOR, p70 S6 kinase, p38 and Caspase‐3 proteins were all down‐regulated in PNO1 KD cells, suggesting the involvement of PNO1 in inflammatory responses, cell cycle regulation, chemotaxis, cell growth and proliferation, apoptosis, cell migration and invasiveness. This study will enhance our understanding of the molecular mechanism of UBC and may eventually provide novel targets for individualized cancer therapy.

• PNO1
• DNA microarray
• bladder cancer
• ingenuity pathway analysis

Endometriosis (EMS) is the most common gynecological disease in women of reproductive age, and it is associated with chronic pelvic pain, dyspareunia and infertility. As a consequence of genetic, immune and environmental factors, endometriotic lesions have high cyclooxygenase (COX)-2 and COX-2-derived prostaglandin E₂ (PGE₂) biosynthesis compared with the normal endometrium. The transcription of the PTGS2 gene for COX-2 is associated with multiple intracellular signals, which converge to cause the activation of mitogen-activated protein kinases (MAPKs). COX-2 expression can be regulated by several factors, such as estrogen, hypoxia, proinflammatory cytokines, environmental pollutants, metabolites and metabolic enzymes, and platelets. High concentrations of COX-2 lead to high cell proliferation, a low level of apoptosis, high invasion, angiogenesis, EMS-related pain and infertility. COX-2-derived PGE₂ performs a crucial function in EMS development by binding to EP2 and EP4 receptors. These basic findings have contributed to COX-2-targeted treatment in EMS, including COX-2 inhibitors, hormone drugs and glycyrrhizin. In this review, we summarize the most recent basic research in detail and provide a short summary of COX-2-targeted treatment.

• COX-2
• PGE2
• endometriosis
• estrogen
• pain

• cyclooxygenase
• cyclooxygenase inhibitors
• cyclooxygénase
• decidua
• déciduale
• fetal membranes
• grossesse
• inhibiteurs de la cyclooxygénase
• labour
• membranes fœtales
• myometrium
• myomètre
• pregnancy
• preterm
• prostaglandines
• prostaglandins
• prématuré
• tocolyse
• tocolysis
• travail

• Indomethacin
• neonatal side effect
• preterm labor
• short cervix

• COX-II
• Cardiotoxic
• Caspase-3
• Doxorubicin
• Fisetin
• cTn-I

• Animals
• Antioxidants/metabolism
• Apoptosis/drug effects
• Cardiotonic Agents/pharmacology
• Cardiotoxicity/drug therapy
• Cardiotoxicity/physiopathology
• Caspase 3/drug effects
• Caspase 3/metabolism
• Cyclooxygenase 2/drug effects
• Cyclooxygenase 2/metabolism
• Doxorubicin/adverse effects
• Doxorubicin/pharmacology
• Flavonoids/metabolism
• Flavonoids/pharmacology
• Flavonols
• Heart
• Inflammation/pathology
• Male
• Myocardium/metabolism
• Nitric Oxide Synthase Type II/drug effects
• Oxidative Stress/drug effects
• Rats
• Rats, Sprague-Dawley
• Troponin I/drug effects
• Troponin I/metabolism
• Tumor Necrosis Factor-alpha/drug effects
• Tumor Necrosis Factor-alpha/metabolism

• Sini decoction
• cyclooxygenase-2
• kidney
• yang deficiency

Studies on the chondrocyte inflammatory injury are very important for understanding the pathogenesis and clinical treatment of osteoarthritis (OA). Evidence suggests that N-methyl pyrrolidone (NMP) may be used as an adjuvant therapy alongside established methods of OA treatment. This study investigated the effect of NMP on chondrocyte inflammatory injury and explored the underlying molecular mechanism.

To mimic the inflammatory injury in vitro, the articular chondrocyte line ATDC5 was simulated with lipopolysaccharide (LPS). ATDC5 cells were treated with various concentrations of NMP (0, 5, and 10 nM). Cell viability was measured using CCK-8 assay; cell apoptosis was detected using FCM; related protein and mRNA expressions were determined using Western blot assay and qRT-PCR assay; and inflammatory factors (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and IL-8) productions were measured by performing ELISA assay.

The results showed that LPS simulation repressed ATDC5 cell viability, prompted cell apoptosis, and enhanced the secretion of inflammatory factors. NMP treatment reduced inflammatory injury induced by LPS in a dose-dependent manner. Furthermore, NMP inhibited the activation of JNK and p38 pathways. In addition, inhibition of NF-κB activation was observed following NMP treatment.

NMP prevents inflammatory reaction of articular chondrocytes via repressing the MAPK/NF-κB pathway. Our findings provide a promising therapeutic agent for OA treatment.

• PKCβII
• RACK1
• eIF3
• eIF4E
• eIF4G
• ribosome
• translation

• Animals
• Biomarkers/metabolism
• Cyclooxygenase 2/metabolism
• Dietary Supplements
• Disease Models, Animal
• Gene Expression Regulation/drug effects
• Inflammation/drug therapy
• Inflammation/metabolism
• Inflammation/pathology
• Inflammatory Bowel Diseases/drug therapy
• Inflammatory Bowel Diseases/metabolism
• Inflammatory Bowel Diseases/pathology
• Male
• Mice
• Mice, Inbred BALB C
• Selenium/pharmacology
• Signal Transduction/drug effects
• Sodium Selenite/pharmacology

• Science and Engineering Research Board (SERB)
• UGC, Govt of India, New Delhi
• University Grants Commission (IN), UGC-SAP program, Govt of India
• Department of Science and Technology, DST-FIST program, Govt of India
• Department of Science and Technology, PURSE Grant, Govt of India